Inmunoexpresión p53, sangre oculta en heces de pacientes colecistectomizados y colelitiasis con adenomas colónicos / P53 Immunoexpression, Faecal Occult Blood from Cholecystectomized Patients and Cholelithiasis with Colonic Adenomas

Introducción: la secuencia adenoma- adenocarcinoma, es resultado de fallos genéticos en las células intestinales heredados o adquiridos. Objetivo: determinar la posible relación entre la inmunoexpresión de la p53 y la positividad de la sangre oculta en heces en los adenomas de colon con alto grado de displasia diagnosticados en pacientes colecistectomizados o con colelitiasis. Métodos: se realizó un estudio descriptivo, de corte transversal, en el Instituto de Gastroenterología, en el período de mayo de 2013 hasta junio de 2015. Se realizaron pruebas estadísticas descriptiva y de chi Cuadrado y probabilidad exacta de Fisher. Resultados: la proporción de adenomas con alto grado de displasia fue similar en pacientes colecistectomizados y con colelitiasis (50 por ciento) respectivamente. Una alta proporción se diagnosticó en colecistectomizados femeninas (35 por ciento), con 60 y más años de edad (53 por ciento) y 11 y más años de colecistectomizados (60 por ciento), mientras que en las colelitiasis fueron masculinos (30 por ciento). Conclusiones: una alta proporción de adenomas con alto grado de displasia presentan inmunoexpresión de la p53 y sangre en heces positiva en pacientes colecistectomizados y con colelitiasis, que se reporta por vez primera(AU)

Introduction: The adenoma - adenocarcinoma sequence is a result of inherited or acquired genetic failures in the intestinal cells. Objective: To determine the immunohistochemical expression of p53 and the positivity of the fecal occult blood test in colon adenomas with high degree of diagnosed dysplasia in cholecystectomized patients or with cholelithiasis. Methods: Descriptive, cross-sectional study conducted in the Institute of Gastroenterology in the period of May, 2013 to June, 2015. Statistical tests were statistics testing, exact Chi Square and Fisher's probability tests. Results: The proportion of adenomas with high degree of dysplasia was similar in cholecystectomized patientsand with cholelithiasis (50 percent) respectively. A high proportion diagnosed in colecistectomizados women (35 percent), 60 and more years of age (53 percent) and 11 and more years of performed cholecystectomy (60 percent), whereas cholelithiasis prevailed in males (30 percent). Conclusions: High proportion of adenomas with high degree of dysplasia present p 53 immunoexpression and positive fecal occult blood test in cholecystectomized patients and patients with cholelithiasis that is reported for the first time(AU)

Immunohistochemical nuclear staining for P53, PCNA, and Ki-67 in different histologic varients of basal cell carcinoma

Structural alternation of P53 gene is a common genetic change associated with basal cell carcinoma [BCC]. Proliferation antigens are expressed in the nuclei of cell during specific stages of the cell cycle including proliferating cell nuclear antigen [PCNA] and Ki-67. Studies have suggested that PCNA and Ki-67 are useful diagnostic tools to differentiate benign from malignant neoplasm and useful prognostic markers in malignant neoplasms. The aim of this work is to detect the expression of P53, PCNA, and Ki-67 in different histologic variants of BCCs, to study the probability of using such markers as diagnostic and prognostic tools. Thirty patients with different histologic variants of BCCs were diagnosed histopathologically. Seven skin biopsies were taken as controls. Immnunohistochemical staining for P53, PCNA, and Ki-67 detection. There is variable degree of positivity of P53, PCNA, and Ki-67 with different histologic variants of BCCs. There is high significant relation between percentage of their positive cells and both aggressiveness and recurrence of BCCs. There is positive relation between P53 and PCNA expression. PCNA expression is greater than Ki-67 in all studied variants except for the superficial variants, which were negative for P53 expression. Both the tumor suppressor gene P53 and the proliferation markers; PCNA and Ki-67 are expressed in BCCs. They are reliable prognostic markers for aggressive behavior of BCCs. They are valuable tool in prediction of possible recurrence. Their staining appeared to be superior to traditional histologic features in predicting clinical recurrence in primary BCC's and further prospective studies in a larger patient group are warranted

Measurment and evaluation of serum anti p53 antibody levels in patients with lung cancer at its initial presentation

The present study aimed to detect and evaluate anti p53 Ab in patients newly diagnosed lung cancer and its relation to histological type, stage of the disease and response to therapy. For this purpose, 48 lung cancer patients at first presentation. 15 patients proven to have pulmonary disease other than lung cancer and 10 apparently healthy subjects were selected for this study. Ten patients from lung cancer group were followed up after treatment. ELISA procedure was used to detect serum anti p53 antibodies in all subjects. There was statistically insignificant difference between cases with positive and negative anti p53 as regards the mean age and sex. Also percentage of positive anti p53 Ab cases in smokers and those accompanied with pleural effusion were significantly higher than in non smokers and those with no pleural effusion. It was found that 27% of lung cancer patients in this study were anti p53 Ab positive with no cell type difference, as there was no statistical significant difference between different histopathological types as regards the positivity of anti p53 [25% squamous cell carcinoma. 20% adenocarcinoma, 33.3% large cell carcinoma and 25% small cell carcinoma] nor regarding the disease stage. Anti p53 Ab was never detected in association with pulmonary diseases other than carcinoma or in control sera. Ten patients [3 positive for anti p53 and 7 negative] were randomly selected where anti p53 was repeated after 6 months of chemotherapy that led to either partial or complete remission of disease, one of them became negative, the other two positive cases showed reduced titer, in already 7 negative cases before treatment, none of them could find anti p53 Ab after treatment so anti p53 Ab could be a useful tool for oncologists in their attempt to analyze the patient response to therapy

Expresión de la proteína del gen supresor de tumores p53 en el carcinoma de próstata / Expression of the supressor gene protein of p53 tumors in prostatic carcinoma

El cáncer de la próstata es una de las neoplasias más frecuentes en hombres mayores de 50 años. La mutación y expresión del gen supresor de tumores p53 ha sido demostrado en la carcinogénesis de múltiples neoplasias y en alrededor del 40 por ciento de los cánceres de la próstata. El objeto de este trabajo es determinar la frecuencia de la expresión del gen p53 en el carcinoma prostático. Se estudia la expresión de la proteína p53 en 35 carcinomas prostáticos mediante la técnica de inmunohistoquímica con anticuerpo monoclonal. Los pacientes se distribuyeron por etapas clínicas: Etapa A = 4 casos; Etapa B = 5 casos; Gleason entre 4 y 7 y el 16 por ciento entre 8 y 10. El promedio de edad fue 70,7 años (límites 53-85 años). No se observó tinción positiva en ninguno de los controles ni en los tumores en etapas A y B. Se observó tinción positiva de la proteína del gen p53 en 11 de los 35 casos (31,4 por ciento), 17 por ciento en los en Etapa C y un 64,2 por ciento tumores en los en Etapa D (p = 0,01). No se observó diferencia respecto del índice de Gleason aun cuando los tumores mejor diferenciados presentaron menor positividad. Nuestros resultados muestran que la proteína del gen supresor de tumores p53 no guarda relación con el índice de Gleason y sólo se observa en tumores avanzados, especialmente en la Etapa D, y su determinación puede contribuir significativamente a una mejor evaluación preoperatoria de los pacientes

a comparative histochemical and immunohistochemical study using angor counts and p53 expression as prognostic indices in ovarian epithelial tumors

In the present study, both P53 expression and AgNOR counts were assessed in epithelial ovarian tumors. P53 was consistently negative in benign cases [n =25]. Atypically proliferate tumors were negative, except for two cases which showed atypia [n =8]. In contrast, 63.2% [n =24] of malignant cases expressed P53 in either focal or diffuse patterns. P53 showed a significant linear association between the three studied groups. A significant linear association was also found between P53 expression and both grade and clinical outcome of epithelial ovarian carcinomas. No significant linear association was found between P53 expression and the clinical stage. Using the simple silver staining technique, a significant difference was found between AgNOR counts of both benign and atypically proliferate tumors on one h and and malignant tumors on the other hand. A significant direct correlation was also seen between AgNOR counts and both grade and stage of epithelial ovarian carcinomas. In addition, a significant difference was seen between responders and partial responders on one side and non-responders on the other side